Stock EH3A AMARIN CORPORATION PLC (ADR)
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Amarin Corporation plc (ADR) Xetra

Equities

EH3A

US0231112063

Real-time Estimate Tradegate
Other stock markets
 07:50:30 2024-06-24 EDT
0.653 EUR 0.00% Intraday chart for Amarin Corporation plc (ADR)
06-12 European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading MT
06-11 European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Tuesday Trading MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Amarin Board of Directors Announces CEO Transition
GL
Amarin Board of Directors Announces CEO Transition
AQ
AMARIN RECEIVES NATIONAL REIMBURSEMENT FOR VAZKEPA IN GREECE AND ANNOUNCES EXCLUSIVE MARKETING AND COMMERCIALIZATION AGREEMENT WITH VIANEX S.A.
AQ
 Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.
GL
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
GL
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
AQ
Amarin: Q1 Earnings Snapshot
AQ
 Amarin Reports First Quarter 2024 Business Update and Financial Results
GL
Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
GL
Amarin Announces Results of Annual General Meeting of Shareholders
GL
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
GL
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
GL
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
AQ
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
AQ
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
GL
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
GL
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe
AQ
Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
GL
Amarin: Q4 Earnings Snapshot
AQ
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AMRN Stock
  4. EH3A Stock
  5. News Amarin Corporation plc (ADR)
  6. Press Releases